Effectiveness of Varenicline: Testing Individual Differences
NCT ID: NCT01228175
Last Updated: 2018-05-09
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
218 participants
INTERVENTIONAL
2010-03-31
2016-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of Safety and Efficacy of Varenicline in Patients That Wish to Stop Smoking
NCT00594204
A 52-Week Placebo-Controlled Study Evaluating the Safety of Varenicline
NCT00143299
A Study To Evaluate The Efficacy And Safety Of Varenicline Compared To Placebo For Smoking Cessation Through Reduction
NCT01370356
Varenicline in Drug Treatment
NCT01286584
Measuring Smoking Behaviors While Using Varenicline
NCT00948155
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Varenicline
Varenicline
Varenicline
Days 1-3 - .5mg tablet 1xdaily Days 4-7 - .5mg tablet 2xdaily Days 8-84 - 1mg tablet 2xdaily
Microcrystal Cellulose
Microcrystal cellulose placebo
Placebo
25mg look alike riboflavin tablets to match active study medication.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
25mg look alike riboflavin tablets to match active study medication.
Varenicline
Days 1-3 - .5mg tablet 1xdaily Days 4-7 - .5mg tablet 2xdaily Days 8-84 - 1mg tablet 2xdaily
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* smoker
Exclusion Criteria
18 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
The Mind Research Network
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kent Hutchison, Ph.D.
Chief Science Officer
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kent Hutchison, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Director, Neurogenetics Core, The Mind Research Network
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Mind Research Network
Albuquerque, New Mexico, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.